Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amarin, Laxdale deal

AMRN will acquire Laxdale (Stirling, U.K.) for 3.5 million AMRN ADSs, which values Laxdale at $2.7 million based on AMRN's July 9 closing price

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE